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Abstract
Background: Osteoarthritis constitutes a major musculoskeletal burden for the aged Australians. Hip and knee replacement
surgeries are effective interventions once all conservative therapies to manage the symptoms have been exhausted. This
study aims to evaluate the cost-effectiveness of hip and knee replacements in Australia. To our best knowledge, the study is
the first attempt to account for the dual nature of hip and knee osteoarthritis in modelling the severities of right and left
joints separately.
Methodology/Principal Findings: We developed a discrete-event simulation model that follows up the individuals with
osteoarthritis over their lifetimes. The model defines separate attributes for right and left joints and accounts for several
repeat replacements. The Australian population with osteoarthritis who were 40 years of age or older in 2003 were followed
up until extinct. Intervention effects were modelled by means of disability-adjusted life-years (DALYs) averted. Both hip and
knee replacements are highly cost effective (AUD 5,000 per DALY and AUD 12,000 per DALY respectively) under an AUD
50,000/DALY threshold level. The exclusion of cost offsets, and inclusion of future unrelated health care costs in extended
years of life, did not change the findings that the interventions are cost-effective (AUD 17,000 per DALY and AUD 26,000 per
DALY respectively). However, there was a substantial difference between hip and knee replacements where surgeries
administered for hips were more cost-effective than for knees.
Conclusions/Significance: Both hip and knee replacements are cost-effective interventions to improve the quality of life of
people with osteoarthritis. It was also shown that the dual nature of hip and knee OA should be taken into account to
provide more accurate estimation on the cost-effectiveness of hip and knee replacements.
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Introduction
Musculoskeletal conditions constitute a major burden to the
Australian population. Over 6.1 million people (of a population of
20 million) were estimated to suffer from a musculoskeletal
condition in 2004 [1]. Musculoskeletal conditions are among the
most frequently managed diseases by general practitioners
accounting for 17% of consultations in 2003–2004 [2]. In 2002,
musculoskeletal conditions were selected as the 7
th National
Health Priority Area [3]. Amongst the various conditions,
osteoarthritis (OA) is the most common type. According to the
Australian Burden of Disease and Injury study 2003 [4], OA
accounted for 34,578 disability-adjusted life-years (DALYs) and
was the largest contributor to musculoskeletal disease burden. The
health expenditure associated with OA was AUD 1.1 billion in
2000-2001, or 25% of all musculoskeletal conditions that was the
third largest component of the total health expenditure accounting
for 9.4% [3]. One of the characteristics of OA is that the
prevalence is higher amongst lower socio-economic quintiles, but
not necessarily among the Indigenous population [5].
Currently there are limited measures to prevent OA, and
there is no absolute cure [3]. However, various non-surgical and
surgical procedures have become available to manage the
symptoms associated with OA and improve physical mobility
and quality of life of the affected population. Guidelines for non-
surgical therapies and surgical referrals have been developed for
general practitioners in Australia [2,6]. Whilst several options
are available for surgical interventions, joint arthroplasty for
hips and knees have been shown to be particularly efficacious to
improve the quality of life of people with OA [7]. Studies from
Australia and other countries have demonstrated hip and knee
replacements to be a cost-effective option [8,9,10,11]. However,
we are not aware of an analysis which accounted for the fact
that people have two hips and two knees, and that within each
pair joints are likely to have different severities of OA.
Evaluations that take only a single joint into account may
overestimate the benefit of surgical intervention because a
sizable proportion of patients have OA in both joints, and pain
relief will therefore be limited.
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hip and knee replacements for OA patients in Australia by
accounting for two joints of the individuals. It was conducted as
part of a large project which compares the cost-effectiveness of
over 150 preventive and curative health interventions in Australia
[12]. Therefore, this study complies with the economic protocol of
the project in order to enable comparisons with all other
interventions. This included the use of disability-adjusted life year
(DALY) as the health outcome measure, which had a major
implication on the methods to model the intervention effects.
Methods
The economic protocol of the parent project of this study
guided the choice of methods for this study. The following sections
provide the details of methods employed for the cost-effectiveness
analysis. Further details are provided in Text S1 that is available
online.
Perspective
A health system perspective was employed for this study.
Although guidelines for economic evaluations often advocate a
societal perspective, the broadest among various alternatives [13],
the most appropriate perspective varies with each study depending
on the target audiences and decision-making contexts. The parent
project of this study aimed to assist policy makers and health
services managers in making practical decisions about what
services to provide within the available resources in the health
sector. Given the aim, a health system perspective was deemed
most appropriate for the project and was adopted in the economic
protocol to which this study mostly adheres.
Discrete-event simulation model
The analysis employed a discrete-event simulation (DES) model.
This type of model has over 50 years of history as a major tool for
operational research [14]. Originally developed in the steel
industry [15], DES models expanded over various sectors
particularly in manufacturing, industry and service sectors [16].
Although the application to the health sector has been less
extensive [14], experts lists healthcare as one of growing priority
areas for DES model application [17]. This is reflected in the
annual number of publications using DES in the healthcare
domain which has nearly doubled since 2004 [18]. Application in
the healthcare setting has been typically in modeling situations
where populations of patients interact with healthcare delivery
system, (e.g. elective surgery, operation room management,
transplantable organ-allocation, patient-flow forecasting), interac-
tion of individuals (e.g. infectious diseases), resource planning, and
economic evaluation [19,20,21].
In economic evaluations, DES model has the flexibility to
accommodate a richer structure without making it unmanage-
able in size [20]. Our study models OA stage progression,
decision for joint replacement, durability and time of repetitive
revisions for each joint separately, which requires a large number
of attributes and events that likely exceeds the manageable size
of a Markov model. Further, the time to event (e.g. decision for
replacement, revision) depends on the time the joints have spent
in the previous attribute. Such ‘‘memories’’ can be attached to
the individuals in a DES model, which is difficult to achieve with
a cohort Markov approach [20]. In a DES model, individual life
histories are created by drawing randomly from distributions
that describe the time to the occurrence of particular events. The
individuals from the study population would move from one
attribute to another, driven by events, by means of time to
progression of OA severity, time to decision for surgery,
probability of surgical success and death, survival time of
implants to revisions, and time to death. We accounted for the
right and left joints for each individual, with in the baseline
analysis the assumption that the attributes of hip or knee joints
are independent of each other (this assumption was examined in
a sensitivity analysis (see Text S1 Section 3.3).
Figure 1 provides the schematic depiction of the model. An
individual aged 40 or over in 2003 enters the model if the person
has at least one joint with moderate OA (grade 2 with symptoms
or grade 3–4 without symptoms) or worse. The other joint may or
may not have OA, but both joints are at risk for progression of OA
severity (or incidence) for some time. Following the assumption set
for the Burden of Disease Study [4], the background mortality rate
for these people was assumed to be higher with a relative risk of
1.1 compared to the rest of population without OA. The person
with OA will receive non-surgical therapies, such as simple
analgesia, non-steroidal anti-inflammatory drugs, land-based
exercise and others, until the OA reaches a severity level that
becomes too difficult to manage. Once the decision for a joint
replacement is made, the person will receive the surgery which
may either be successful (the DW of the joint will improve by the
estimated effect size, either with complications or without) or
unsuccessful (surgical death). After a successful replacement of a
joint, the implant will function for a certain time until an event
prompts a revision (e.g. dislocation, loosening etc.). The process of
surgery and implant failure will repeat for each OA affected joint
for life.
In modelling such events for each individual, we have drawn
parameters from various sources. The information on the
progression of OA severities was obtained from the Bristol OA
500 study [22] which followed-up patients with OA for eight years.
The time to decision of surgery was modelled from the annual
surgical rate among severe OA patients, which was calculated as
the proportion of surgeries reported in the National Joint
Replacement Registry [23] for 2003 and the number of OA
patients at grade 3–4 (symptomatic) from the Burden of Disease
study. The time to revision of implants was modelled by
distinguishing short- and long-term causes. The information on
the time to failure of implants due to short-term causes was
obtained from the revision rates over seven years reported in the
National Joint Replacement Registry [24]. The information on
long-term causes was obtained from follow-up studies in
international literature. We assumed separate Weibull distribu-
tions for short- and long-term causes for implant failures. The
probability density curves for implant failures from the two
Weibull distributions were then combined to a mixture distribu-
tion, normalized (i.e. the surface under the mixture distributions
equals unity) and adjusted to fit the observed values by means of
the Solver function in MS-Excel. Figure 2 provides an example of
the combined distribution curve of time to revision of hip implants
(see Text S1 Section 1.9 for further details of methods and
outputs).
In simulating the progression of OA severity, time to decision of
surgery and time to implant failure for each individual, we
converted each estimated parameter to a continuous survival curve
from which random draws determined the time to the next events.
Other events, such as death from surgery, were determined by
assessing the outcome of a Bernoulli trial based on the probabilities
of such events obtained from literature (see Text S1 Section 1.6).
The model was implemented in MS-Excel, using the Ersatz add-in
[25] to perform the simulation. Table 1 provides the sources of
information from which the input parameters were obtained.
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The study population comprised of Australians with OA who
were 40 years of age or older in 2003 as was estimated in the
Australian Burden of Disease and Injury study. In the Burden of
Disease study, OA was divided into four grades with different
disability weights (DWs) assigned (see Table 2 and Text S1 Section
1.8) [4,66]. We limited the inclusion to males and females who had
at least one hip or knee with grade 2 symptomatic OA or higher.
The number of individuals for each sex/age-group was obtained
from the Burden of Disease study. The study did not distinguish
people with hip and knee OA. We therefore assumed that the
proportion of hip and knee OA was the same as the age-group
specific proportions of hip and knee replacement surgeries
conducted in Australia in 2003 [23]. 68,908 individuals (30,347
males and 38,561 females) with hip OA and 100,657 individuals
(42,930 males and 57,727 females) with knee OA entered the
analysis and were followed-up until extinct.
Interventions
The interventions are total replacement of hips and knees.
Whilst alternative methods are available for primary surgeries (i.e.
hip resurfacing, uni-compartmental knee arthroplasty etc.), only
primary conventional total hip replacements and primary total
knee replacements, as defined in the National Joint Replacement
Registry [23], including their subsequent revisions, were consid-
ered in this analysis as they constitute the majority of surgeries in
Australia (91% of OA primary hip, 86% of OA primary knee)
[24], and the evidence on efficacy of other types of implants has
yet to be well established. All patients were assumed to have
received a series of non-surgical treatments until these become
insufficient prior to the decision to undergo surgery. The
comparator for both hip and knee replacements is ‘doing nothing’
(continued non-surgical therapies without joint replacements).
OA is a chronic non-fatal disease which significantly affects the
well-being of patients. Surgical intervention primarily aims to
Figure 1. Event pathway of people with osteoarthritis in the discrete-event simulation model.
doi:10.1371/journal.pone.0025403.g001
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and knee replacement surgeries have been evaluated by various
instruments in the literature. Such instruments can range from
generic (e.g. SF-36: Medical Outcomes Study Short-Form 36;
HAQ: Health Assessment Questionnaire) [67,68], arthritic-specific
(e.g. WOMAC: Western Ontario and McMaster University
Osteoarthritis Index) [69], or utility (e.g. EQ-5D: EuroQol 5-
dimensions [70]). As mentioned, we used the DALY disability
weight (DW) from the Burden of Disease study to quantify the
impact of OA on the quality-of-life faced by OA patients.
However, we were not able to identify any literature utilizing this
instrument to measure the effect of hip and knee replacement.
Therefore, we estimated the effect size on the DW from literature
utilizing other instruments in the following manner:
Effect~ 1{Scorepost
  
= 1{Scorepre
  
ð1Þ
DWpost~DWpre   Effect ð2Þ
where Effect denotes the effect size of an intervention, Scorepost the
single index of post-surgery scores from other instruments, Scorepre
the single index of pre-surgery score of other instruments, DWpost
the DW at post-surgery, and DWpre the DW at pre-surgery. For
instruments that do not use scores that fall between 0 and 1, we
adjusted the scores to fall within this range (e.g. HAQ uses scores
between 0 and 3, so we divided the scores by 3). The underlying
assumptions for this novel approach were two. First, although the
scores used in other instruments are fundamentally different and
are not comparable to each other, the ratios between pre- and
post-intervention scores in each instrument reflect the same
relative health improvements from the intervention. Second, the
effect sizes calculated as per the above equation are comparable
between instruments and serve as proxies for the effects on the
DWs. In order to test for the plausibility of this technique, a
sensitivity analysis was performed to compare the cost-effectiveness
results between DALY and EQ-5D as health outcome measures
for hip replacements where both results proved fairly comparable
(see Text S1 Section 3.3).
We used different approaches to calculate Scorepre and Scorepost for
hip and knee replacements depending on the available data. To
calculate the scores for hip replacements, we used the regression
model from Briggs et al. [46] which they employed to estimate the
pre- and post-surgical quality of life scores of hip replacements
using EQ-5D. We assumed normal distributions to each regression
coefficient and calculated the pre- and post-surgical quality of life
scores, which were then assigned to Expressions 1 and 2 to
extrapolate the post-surgical DW.
On the other hand, we were not able to identify an appropriate
source for knee replacement providing a regression model like this.
Therefore, we used the literature included in a systematic review [7]
reporting the pre-and post-surgical scoresof knee replacementsin EQ-
5D, HAQ, and SF-36. We performed a non-parametric bootstrap on
Expression 1 with 5,000 iterations by assigning the scores reported in
13 primary studies with 16 indexes (i.e. one EQ-5D, one HAQ, and
fourteen SF-36 indexes) to derive the mean effect sizes and confidence
intervals [47,48,49,50,51,52,53,54,55,56,57,58,71]. In order to derive
a single score from studies using SF-36, we referred to the transfer to
utility (TTU) technique, a tool developed by Segal et al. [8] to convert
the multiple sub-scales of SF-36 to a single utility score for OA and
subsequently applied to stroke [72]. In recognition of the critique
raised by Viney et al. [73] regarding the TTU due to the fundamental
differences between the concepts underlying health-related quality of
life-scores and utilities, our aim was to estimate the effect size of the
intervention under the assumptions set out above rather than to
Figure 2. Cumulative distribution curve of time to revision with observed values (hip implants).
doi:10.1371/journal.pone.0025403.g002
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compare the cost-effectiveness of disparate interventions, and in the
absence of evidence on the effect size of hip and knee replacements on
DWs, we regarded the TTU technique as an acceptable tool. Table 3
shows the estimated effect sizes on DWs (refer to Text S1 Section 1.8
for further details).
The health gains from the interventions were expressed as
DALYs averted which were calculated using the following
equation:
DALYs averted ~
X
1-PYLDa ðÞ   1-DW1post
  
  1-DW2post
     
-
X
1-PYLDa ðÞ   1-DW1pre
  
  1-DW2pre
     
ð3Þ
where PYLDa denotes the prevalent years lived with disabilities
(excluding those due to OA) of a person at age a since the time of
primary joint replacement (for the intervention arm) or the time
Table 1. Data sources.
Parameters Sources of information
Population and demographic
Population Burden of Disease 2003 [4]
Mortality rate Burden of Disease 2003
Prevalent years lived with disability Burden of Disease 2003
OA
Prevalence (all) National health survey 2001 [1]
Prevalence (grade 2 symptomatic+) Burden of Disease 2003
Proportion of number of people in each grade Burden of Disease 2003, literature [26,27]
Mortality relative risk (OA) Burden of Disease 2003
Progression of OA severity Literature[22], Burden of Disease 2003
Proportion of bilateral OA Literature [28,29,30,31,32,33,34,35,36]
DW Burden of Disease 2003
Intervention (hip and knee replacement)
Proportion of OA as primary diagnosis Joint replacement registry 2007 [37]
Number of operations Joint replacement registry 2004 [23]
Surgical death rate CIHI 2007 [38], Joint replacement registry 2007
Revision rate (short term) Joint replacement registry 2008 [24]
Revision rate (long term) Literature [39,40,41,42,43,44,45]
Effect Literature [7,46,47,48,49,50,51,52,53,54,55,56,57,58]
Cost
Hip and knee replacement surgery Australian hospital statistics (2003-04), National hospital cost data collection (2003–2004)
[59,60]
Health expenditure for OA and all other health conditions Disease costing and impact study (2000-01) [61]
Patient’s out of pocket payment Literature [62]
Patient’s time cost Average weekly earnings [63], Labour Force Statistics 2003 [64]
Price deflator Health expenditure in Australia (2003-04) [65]
OA: osteoarthritis; CIHI: Canadian Institute for Health Information.
doi:10.1371/journal.pone.0025403.t001
Table 2. Case definition and sequelae.
OA sequelae Definition
Grade 2 (radiological) Definite osteophytes in hip or knee
Grade 2 (symptomatic) Grade 2 and pain for at least 1 month in last 12
Grade 3-4 (asymptomatic) Osteophytes and joint space narrowing in hip or knee,
deformity also present for Grade 4
Grade 3-4 (symptomatic) Grade 3+ and pain for at least 1 month in last 12
OA: osteoarthritis.
Source: The burden of disease and injury in Australia 2003 [4].
doi:10.1371/journal.pone.0025403.t002
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person were to receive it (for the comparator arm), and DW1post/pre
and DW2post/pre the disability experienced by the first and second
joints for the person with and without joint replacements.
Intervention Cost and Cost Offset
Given the health system perspective employed for this study, all
costs that fall on the health sector with the interventions were
included in the analysis, both in the government and private sectors.
The private sector costs included those born by the patients such as
co-payment, travel costs and time costs. Health sector costs that can
be saved due to the interventions are also included in the analysis.
Costs for surgeries were derived from the average cost per
diagnosis-related group in 2003 [59,60] and the disease costing
and impact study 2000-2001 [61]. We distinguished the surgical
costs between primary replacements and revisions, and with and
without complications. The probability of having complications
for primary replacements and revisions were extrapolated from the
proportion of complications in 2003, which were estimated from
the reports of National Joint Replacement Registry and cost per
diagnosis-related group. A random value from the Bernoulli trial
determined the presence or absence of complications for the
individuals in the simulation (see Text S1 Section 2.1).
Patient’s out of pocket costs related to surgery were obtained
from March et al. [62] assuming that the personal spending which
accrue three months pre- and post surgery is part of the intervention
costs. Patient’s time costs were defined as those directly involved in
receiving surgery-related services including travelling, waiting, pre-
surgical visits, operation and recuperation. Unit costs associated
with patient’s time were obtained from the average weekly earnings
in 2003 [63]. Future costs which are to be offset as the result of
interventions were calculated from the annual OA expenditure
obtained from disease costing and impact study 2000-2001 [61].
Unrelated health care costs, which would accumulate in the future
due to extended life years of OA patients after joint replacements,
were also obtained from the same source. Further details of the
estimation of different costs are provided in Text S1 Section 2. The
full data sources and estimatedinterventioncosts aresummarized in
Tables 1 and 4. The exchange rate for Australian dollar (AUD) in
2003 was 1 AUD=0. 67 USD (07/01/2003) [74]. The costs
obtained from different years were all adjusted to the AUD 2003
value by means of price deflator [65].
Accounting for Uncertainties
Uncertainty distributions were provided for input parameters
where appropriate in order to account for sampling uncertainties.
The model underwent Monte Carlo simulation (often also known
as probabilistic sensitivity analysis) by re-sampling the values of
parameters 2,000 times from the given distributions. The
distributions provided for each parameter are shown in Table 5.
The model was implemented in Microsoft Excel 2007, with the
Ersatz add-in [25] for uncertainty analysis. We conducted the
simulation under different scenarios based on the inclusion or
exclusion of cost offset and patient’s time cost. Future costs and
health gains were discounted at an annual rate of 3% to account
for time preference. The internal consistency of model was tested
by comparing the proportions of total joint replacements occurring
in each sex/age-group for a given year between the joint registry
[23] and our simulation.
Results
Among those who have undergone successful hip and knee
replacement surgeries at least once, 49% of males and 42% of
females with hip OA had their second joints replaced along their
course of life. The proportions of bilateral replacements for people
with knee OA were 57% and 52% for males and females
respectively. The test for internal consistency provided reasonably
comparable outputs between the joint registry and our simulation
(see Text S1 Section 3.4). Tables 6, 7, and 8 provide the costs,
health gains, and incremental cost-effectiveness ratios (ICERs) and
95% uncertainty intervals (UIs) (sex-specific results provided in
Text S1 Section 3.1). The results are reported at the population-
level due to the aim of this study to inform policy makers at the
national-level. While the protocol of the parent project of this
study excluded the unrelated health care costs that would
accumulate in the future due to prolonged life-years of patients
[12], we report the results with the inclusion of such costs as an
additional scenario (Table 9). Both hip and knee replacements
were cost-effective compared to the pre-defined threshold level of
AUD 50,000 per DALY averted by the overarching project of this
study [12]. Although the ICERs become less favourable if we
excluded the cost offset, or included the future unrelated health
care costs, they are consistently below the threshold level. The
scatter plots of hip and knee replacements are provided in Figure 3.
Discussion
This study has found favourable cost-effectiveness for hip and
knee replacement in Australia. Given the sizable burden of OA in
Australia, the interventions contribute substantially to the
improvement of people’s quality of life at reasonable costs.
However, there were substantial differences in the cost-effective-
Table 3. Effect size of hip and knee replacements on disability-weights.
Joint Type Sex Mean SD LCI 95% HCI 95%
Hip Primary Male 0.3358 0.0454 0.2548 0.4319
Female 0.3479 0.0376 0.2793 0.4260
Revision Male 0.5339 0.0830 0.3883 0.7115
Female 0.5527 0.0709 0.4256 0.7018
Knee Primary Male 0.5202 0.0697 0.3888 0.6606
Female 0.5205 0.0687 0.3891 0.6580
Revision Male 0.6610 0.0492 0.5642 0.7573
Female 0.6698 0.0474 0.5772 0.7621
SD: standard deviation; LCI: lower confidence interval limit; HCI: higher confidence interval limit.
doi:10.1371/journal.pone.0025403.t003
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Cost item Cost per surgery (AUD)
Government cost
Hip replacement surgery (primary–Cscc) 13,648
Hip replacement surgery (primary+Cscc & revision–Cscc) 16,744
Hip replacement surgery (revision+Cscc) 30,648
Knee replacement surgery (primary–Cscc) 13,640
Knee replacement surgery (primary+Cscc & revision–Cscc) 19,620
Knee replacement surgery (revision+Cscc) 35,912
Other costs related to surgery (non-admitted visits etc.) 2,254
Patient out of pocket cost
Out of pocket cost pre- and post-surgery (hip) 839
Out of pocket cost pre- and post-surgery (knee) 1,019
Time cost
Pre-surgical visits (hip) 168
Surgery & recuperation (hip, male, primary–Cscc) 2,227
Surgery & recuperation (hip, male, primary+Cscc & revision–Cscc) 3,781
Surgery & recuperation (hip, male, revision+Cscc) 5,629
Surgery & recuperation (hip, female, primary–Cscc) 1,576
Surgery & recuperation (hip, female, primary+Cscc & revision–Cscc) 2,677
Surgery & recuperation (hip, female, revision+Cscc) 3,985
Pre-surgical visits (knee) 171
Surgery & recuperation (knee, male, primary–Cscc) 2,096
Surgery & recuperation (knee, male, primary+Cscc & revision–Cscc) 4,197
Surgery & recuperation (knee, male, revision+Cscc) 6,246
Surgery & recuperation (knee, female, primary–Cscc) 1,484
Surgery & recuperation (knee, female, primary+Cscc & revision–Cscc) 2,970
Surgery & recuperation (knee, female, revision+Cscc) 4,422
Cscc: catastrophic or severe complications and comorbidities.
doi:10.1371/journal.pone.0025403.t004
Table 5. Distributions assumed for each parameter.
Parameters Distributions
Time to primary replacement of hip and knee joints
* Empirical
Time to death
* Empirical
Time to revision of hip and knee implants
* Weibull
{
Intervention effect (regression coefficients for hip replacement) Normal
{
Intervention effect (knee replacement) Beta
{
Intervention cost (hip and knee surgeries) Gamma
1
Patient’s out of pocket payment pre/post-surgeries Gamma
1, Triangular
**
Patient’s time cost for surgeries Gamma
1, Triangular
**
Average length of stay for hip and knee surgeries and recuperations Gamma
1
*These parameters accounted for the first-order uncertainties (individual level), and others the second-order uncertainties (population level).
{Time to failure due to short-run and long-run causes were distinguished. We assumed separate Weibull distributions for each cause, and modelled the time to revision
as the normalized sum of these two. The Weibull parameters are provided in Text S1 Section 1.9.
{The values are provided in Text S1 Section 1.8.
1The parameters of Gamma distributions consist of Alpha = unit cost, Beta = 1.
**Triangular distribution was used to model the uncertainty of unit costs (620%), and Gamma distribution for the time spent in hospital.
doi:10.1371/journal.pone.0025403.t005
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substantially more cost-effective than knee replacements. The
ICER for knee replacements without cost offsets was AUD 21,000,
or AUD 26,000 including unrelated health care costs, per DALY
averted with time costs, and was about half that for hip
replacements (AUD 12,000, or AUD 15,000 including unrelated
health care costs, per DALY). The difference became slightly more
prominent if we included the cost offsets in the analysis (ICER for
knee: AUD 12,000, or AUD 17,000 including unrelated health
care costs, per DALY with time costs; ICER for hip: AUD 5,000,
or AUD 8,600 including unrelated health care costs, per DALY).
There are a number of reasons for the more favourable results of
hip replacements. First, the post-surgery health outcomes for hip
replacements consistently surpass that for knee replacements in the
literature [7]. This was reflected in our result where the cumulative
health benefits was similar for hip and knee replacements despite
the smaller number of people included in the hip replacement
analysis (see Table 6). Second, more revisions were required for
knee replacements (see Text S1 Section 1.10). Since a hip
replacement provides better health outcome at lower costs
compared to a knee replacement, it is more cost-effective.
Although females have slightly more favourable ICERs for both
hip and knee replacements, the UIs largely overlap with those of
males. On the other hand, the ICERs can substantially vary
between age-groups. Age-group specific results are provided in
Text S1 Section 3.2 which shows less favourable ICERs for elderly
patients, yet mostly within the threshold level.
An earlier study in Australia by Segal et al. [8] also reported
favourable cost-effectiveness for joint replacements (AUD 4,535 –
6,953 per QALY for hip replacement and AUD 7,671 – 11,671
for knee replacement) although the findings are noticeably more
favourable than ours (AUD 9,000 – 12,000 per DALY for hip
replacement and AUD 16,000 – 23,000 per DALY for knee
replacement, without cost offset, time cost, and unrelated health
care cost) and not directly comparable due to methodological
differences. Studies from other countries suggest the cost-
effectiveness of hip replacement ranges between cost-saving and
AUD 10,900 per QALY, and between AUD 9,000 and 24,400 per
QALY for knee replacement [9,10,11]. In order to make the
results from our study more comparable to the other ones, we
conducted a sensitivity analysis by restricting one joint of all
individuals to be free from OA for life (unilateral OA for both hips
and knees), and by replacing the health outcome measure from
DALY to QALY (EQ-5D) for hip replacement (this was difficult
for knee replacement since the employed effect size was a pooled
product from multiple studies using different instruments). The
results from the analysis where one joint was always free from OA
were AUD 6,900 per DALY and AUD 11,000 per DALY for hip
and knee replacements, respectively (Text S1 Section 3.3). Further,
replacing the health outcome measure for hip replacement to
QALY and restrict one hip to be free from OA provided a cost-
effectiveness ratio of AUD 6,500 per QALY (Text S1 Section 3.3).
Interestingly all these results fell within the range of the ones from
Segal et al., which support the hypothesis that accounting for only
Table 6. Health gains.
Hip (DALY averted) Knee (DALY averted)
Mean 95%UI Mean 95%UI
DALY averted 115,000 98,800 – 129,000 113,000 93,200 – 133,000
DALY averted
(per person)
*
1.7 per person 1.1 per person
DALY: disability-adjusted life-years; UI: uncertainty interval.
NB: The values are discounted by 3%, and rounded to the three digits of significance.
* Mean value divided by the number of people (68,908 for hip, 100,657 for knee).
doi:10.1371/journal.pone.0025403.t006
Table 7. Costs under different scenarios.
Scenario Hip (AUD Millions) Knee (AUD Millions)
Mean 95%UI Mean 95%UI
With cost offset
Without time cost 420 400 – 440 1,100 1,100 – 1,200
With time costs 580 520 – 670 1,400 1,300 – 1,500
Without cost offset
Without time cost 1,200 1,100 – 1,200 2,100 2,100 – 2,200
With time costs 1,300 1,300 – 1,400 2,400 2,300 – 2,500
Cost per person
*
With cost offset (without time costs) 6,100 per person 11,000 per person
Without cost offset (without time cost) 17,000 per person 21,000 per person
AUD: Australian Dollar; UI: uncertainty interval.
NB: The values are discounted by 3%, and rounded to the two digits of significance.
*Mean value without time cost (unit: AUD) divided by the number of people in the model.
doi:10.1371/journal.pone.0025403.t007
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ratios for hip and knee replacement surgeries.
Our analysis made a number of assumptions and has some
limitations which are worth noting. First the quantification of the
intervention effects was problematic. Whilst the change in the
DALYDWplaysakeyroleinmeasuringtheinterventioneffects,we
were not able to identify studies utilizing this instrument to measure
the effects of hip and knee replacements. Therefore we extrapolated
the effects from other instruments with assumptions which
potentially could have under- or over-estimated the true DW
post-interventions. However, the extrapolations were in line with
the findings from a systematic review that the post-replacement
indexes are consistently better than pre-surgery, and hip replace-
ments have consistently better health outcomes than knee
replacements. Further, as mentioned above, the sensitivity analysis
comparing the results between DALY and EQ-5D as health
outcome measures suggested the plausibility of these assumptions.
Another limitation was that the durability of hip and knee
implants were modelled from historical data, which may be under
estimating the current survivorship of implants given the
technological advancement over decades. This issue has poten-
tially resulted in a less favourable cost-effectiveness, since an
improved durability of implants would reduce the number of
revisions. Further, the revision rates of hip implants obtained from
the National Joint Replacement Registry included replacement
cases due to fractured neck of femur which are known to have a
shorter lifespan than from other causes and were not included in
our study population. This may have potentially caused an under-
estimation of the true survivorship of implants. However, the
proportion of replacements due to fractures is small (2.8% between
1999 and 2004) [75], and so is not likely to have affected the
estimation substantially.
The independence of OA progression and time to revision of
implants assumed for the right and left joints warrants due
attention. Whilst some correlation may exist between the two
joints, the actual degrees are unknown. Therefore we performed a
sensitivity analysis by assuming an extreme correlation between
the two joints; i.e. 60.99. The analysis did not provide significant
deviations from our original results (see Text S1 Section 3.3), and
so our findings are robust with respect to this assumption.
On the other hand, the study has its own strength. The nature
of the intervention, which may or may not require repeated
revisions at varying intervals for one or two joints, favoured the
employment of a DES model. The model has the potential to
account for variations at both (or either) individual levels (first
order) and population levels (second order). This is one of the
advantages of this study which would reflect the variations at the
population level more accurately. Another strength was that the
model was able to account for two hips or knees for each
individual with OA. Modelling two joints separately for a person
would have been difficult with other approaches. As discussed
above, modelling just one joint overestimates health benefits since
a sizable proportion of OA patients suffer from bilateral problems
and hence replacement of one joint will leave the problem on the
other joint. In this regard, a further study that account for OA
problems in multiple sites of a patient (i.e. both hip and knee joints)
may be warranted as more epidemiological data on OA become
available.
In conclusion, the findings suggest that both hip and knee
replacements are highly cost-effective with ICERs significantly
lower than the AUD 50,000 per DALY threshold level. The
interventions substantially contribute to the improvement of
quality of life of population suffering from OA. Despite the
limitations of the study, the overall conclusions from the analysis
Table 8. Incremental cost-effectiveness ratio.
Scenario Hip (AUD per DALY averted) Knee (AUD per DALY averted)
Mean 95%UI Mean 95%UI
With cost offset
Without time cost 3,600 3,200 – 4,200 10,000 8,400 – 12,000
With time costs 5,000 4,200 – 6,200 12,000 10,000 – 15,000
Without cost offset
Without time cost 10,000 9,000 – 12,000 19,000 16,000 – 23,000
With time costs 12,000 10,000 – 13,000 21,000 18,000 – 26,000
AUD: Australian Dollar; DALY: disability-adjusted life-years; UI: uncertainty interval.
NB: The values are discounted by 3%, and rounded to the two digits of significance.
doi:10.1371/journal.pone.0025403.t008
Table 9. Incremental cost-effectiveness ratio including future unrelated health care costs.
Scenario Hip (AUD per DALY averted) Knee (AUD per DALY averted)
Without time cost With time cost Without time cost With time cost
With cost offset 7,100 8,600 15,000 17,000
Without cost offset 13,000 15,000 24,000 26,000
AUD: Australian Dollar; DALY: disability-adjusted life-years.
NB: The values are discounted by 3%, and rounded to the two digits of significance.
doi:10.1371/journal.pone.0025403.t009
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the dual nature of hip and knee OA into account to provide more
accurate estimation on the cost-effectiveness of hip and knee
replacements.
Supporting Information
Text S1 Details of methods, input data and additional results.
(PDF)
Acknowledgments
The authors greatly acknowledge Dr. Scott Crawford, Director of
Orthopaedic Surgery, Prince Charles Hospital, for his technical advice
on joint replacement surgeries, and Professor Robert Carter, Deakin
University, for his advice on the costing part of the analysis.
Author Contributions
Analyzed the data: HH JJB. Contributed reagents/materials/analysis tools:
HH JJB. Wrote the paper: HH JJB.
References
1. Australian Bureau of Statistics (2006) National health survey: summary of results,
2004-05. Canberra: Australian Bureau of Statistics.
2. The Royal Australian College of General Practitioners (2009) Guideline for the
non-surgical management of hip and knee osteoarthritis. Melbourne: The Royal
Australian College of General Practitioners.
3. Australian Institute of Health and Welfare (2005) Arthritis and musculoskeletal
conditions in Australia, 2005. Canberra: Australian Institute of Health and
Welfare.
4. Begg S, Vos T, Barker B, Stevenson C, Stanley L, et al. (2007) The burden of
disease and injury in Australia 2003. Canberra: Australian Institute of Health
and Welfare.
5. National Arthritis and Musculoskeletal Conditions Advisory Group (2005) A
national action plan for osteoarthritis, rheumatoid arthritis and osteoporosis: a
national health priority area. Canberra: Australian Government Department fo
Health and Ageing.
6. The Royal Australian College of General Practitioners (2007) Referral for joint
replacement: a management guide for health providers. Melbourne: Joint
Replacement Waiting List Working Group, The Royal Australian College of
General Practitioners.
7. Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY (2004) Health-
related quality of life in total hip and total knee arthroplasty. A qualitative and
systematic review of the literature. J Bone Joint Surg Am 86-A: 963–974.
8. Segal L, Day S, Chapman A, Osborne R (2004) Priority setting in osteoarthritis.
Melbourne: Centre for Health Economics, Monash University.
9. Lavernia C, Guzman J, Gachupin-Garcia A (1997) Cost effectiveness and
quality of life in knee arthroplasty. Clin Orthop 1: 134–139.
10. Chang RW, Pellisier JM, Hazen GB (1996) A cost-effectiveness analysis of total
hip arthroplasty for osteoarthritis of the hip. Journal of the American Medical
Association 275: 858–865.
11. Rissanen P, Aro S, Sintonen H, Asikainen K, Sla ¨tis P, et al. (1997) Costs and
cost-effectiveness in hip and knee replacements: aprospectivestudy. IntJTechnol
Assess Health Care 13: 574–588.
12. Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman L, et al. (2010)
Assessing cost-effectiveness in prevention (ACE-Prevention): Final report.
Brisbane and Melbourne: University of Queensland, Deakin University.
13. Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers
of economic submissions to the BMJ. BMJ 313: 275–283.
14. Taylor SJE, Eldabi T, Riley G, Paul RJ, Pidd M (2009) Simulation modelling is
50! Do we need a reality check? J Oper Res Soc 60: S69–S82.
15. Hollocks BW (2006) Forty Years of Discrete-Event Simulation: A Personal
Reflection. The Journal of the Operational Research Society 57: 1383–
1399.
16. Cao X, Day S, Shah S, McGee S (2006) Discrete event simulation in
pharmaceutical research-a package line model. In: Robinson S, Taylor S,
Brailsford S, Garnett J, eds. Birmingham. pp 1123–1130.
17. Taylor SJE, Robinson S (2006) So where to next? A survey of the future for
discrete-event simulation. Journal of Simulation 1: 1–6.
18. Guenal MM, Pidd M (2010) Discrete event simulation for performance
modelling in health care: a review of the literature. Journal of Simulation 4:
42–51.
19. Weinstein MC (2006) Recent Developments in Decision-Analytic Modelling for
Economic Evaluation. Pharmacoeconomics 24: 1043–1053.
20. Barton P, Bryan S, Robinson S (2004) Modelling in the economic evaluation of
health care: selecting the appropriate approach. J Health Serv Res Policy 9:
110–118.
21. Comas M (2008) Application of discrete-event simulation to health services
research: analysis of needs and demand for elective surgery. Barcelona:
Universitat Polite `cnica de Catalunya.
Figure 3. Cost-effectiveness of hip and knee replacements illustrated on a cost-effectiveness plane with AUD 50,000 per DALY
threshold line (without time cost). The graphs represent population total rather than per patient outcomes (hip replacement: 68,908 individuals;
knee replaceement: 100,657 individuals).
doi:10.1371/journal.pone.0025403.g003
Cost-Effectiveness of Hip and Knee Replacements
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e2540322. Dieppe P, Cushnaghan J, Tucker M, Browning S, Shepstone L (2000) The
Bristol ‘OA500 study’: progression and impact of the disease after 8 years.
Osteoarthritis Cartilage 8: 63–68.
23. Australian Orthopaedic Association National Joint Replacement Registry (2004)
Annual report. Adelaide: Australian Orthopaedic Association.
24. Australian Orthopaedic Association National Joint Replacement Registry (2008)
Annual report. Adelaide: Australian Orthopaedic Association.
25. Epigear (2010) Ersatz 1.1. Brisbane: Epigear International PTY LTD.
26. Guccione A, Felson D, Anderson J (1990) Defining arthritis and measuring
functional status in elders: methodological issues in the study of disease and
physical disability. Am Public Health Assoc. pp 945–949.
27. Felson D (1990) The epidemiology of knee osteoarthritis: results from the
Framingham Osteoarthritis Study. Semin Arthritis Rheum 20: 42–50.
28. Dawson J, Linsell L, Zondervan K, Rose P, Randall T, et al. (2004)
Epidemiology of hip and knee pain and its impact on overall health status in
older adults. Rheumatology 43: 497–504.
29. Tepper S, Hochberg MC (1993) Factors associated with hip osteoarthritis: data
from the first national health and nutrition examination survey (NHANES-1).
Am J Epidemiol 137: 1081–1088.
30. Hochberg M, Lethbridge-Cejku M, Scott W, Reichle R, Plato C, et al. (1995)
The association of body weight, body fatness and body fat distribution with
osteoarthritis of the knee: data from the Baltimore Longitudinal Study of Aging.
J Rheumatol 22: 488–493.
31. Mannoni A, Briganti MP, Di Bari M, Ferrucci L, Costanzo S, et al. (2003)
Epidemiological profile of symptomatic osteoarthritis in older adults: a
population based study in Dicomano, Italy. Ann Rheum Dis 62: 576–578.
32. Ingvarsson T, Hagglund G, Lohmander LS (1999) Prevalence of hip
osteoarthritis in Iceland. Ann Rheum Dis 58: 201–207.
33. Davis MA, Ettinger WH, Neuhaus JM (1990) Obesity and osteoarthritis of the
knee: evidence from the national health and nutrition examination survey
(NHANES I). Semin Arthritis Rheum 20: 34–41.
34. Zhang Y, Xu L, Nevitt MC, Aliabadi P, Yu W, et al. (2001) Comparison of the
prevalence of knee osteoarthritis between the elderly Chinese population in
Beijing and whites in the United States: The Beijing osteoarthritis study.
Arthritis & Rheumatism 44: 2065–2071.
35. Ledingham J, Regan M, Jones A, Doherty M (1995) Factors affecting
radiographic progression of knee osteoarthritis. Ann Rheum Dis 54: 53–58.
36. Lacey R, Thomas E, Duncan R, Peat G (2008) Gender difference in
symptomatic radiographic knee osteoarthritis in the Knee Clinical Assessment
- CAS(K): a prospective study in the general population. BMC Musculoskeletal
Disorders 9: 82.
37. Australian Orthopaedic Association National Joint Replacement Registry (2007)
Annual report. Adelaide: Australian Orthopaedic Association.
38. Canadian Institute for Health Information (2007) Canadian joint replacement
registry report: total hip and total knee replacements in Canada. Ottawa:
Canadian Institute for Health Information.
39. Schulte KR, Callaghan JJ, Kelley SS, Johnston RC (1993) The outcome of
Charnley total hip arthroplasty with cement after a minimum twenty-year
follow-up. The results of one surgeon. J Bone Joint Surg Am 75: 961–975.
40. Callaghan JJ, Albright JC, Goetz DD, Olejniczak JP, Johnston RC (2000)
Charnley total hip arthroplasty with cement: minimum twenty-five-year follow-
up. J Bone Joint Surg Am 82: 487–497.
41. Callaghan JJ, Templeton JE, Liu SS, Pedersen DR, Goetz DD, et al. (2004)
Results of Charnley total hip arthroplasty at a minimum of thirty years. A
concise follow-up of a previous report. J Bone Joint Surg Am 86: 690–695.
42. Madey SM, Callaghan JJ, Olejniczak JP, Goetz DD, Johnston RC (1997)
Charnley total hip arthroplasty with use of improved techniques of cementing.
The results after a minimum of fifteen years of follow-up. J Bone Joint Surg Am
79: 53–64.
43. Schreurs BW, Bolder SBT, Gardeniers JWM, Verdonschot N, Slooff TJJH, et
al. (2004) Acetabular revision with impacted morsellised cancellous bone grafting
and a cemented cup: A 15- to 20-year follow-up. J Bone Joint Surg Br 86-B:
492–497.
44. Rand JA, Trousdale RT, Ilstrup DM, Harmsen WS (2003) Factors affecting the
durability of primary total knee prostheses. J Bone Joint Surg Am 85-A:
259–265.
45. Rand J, Ilstrup D (1991) Survivorship analysis of total knee arthroplasty.
Cumulative rates of survival of 9200 total knee arthroplasties. J Bone Joint Surg
Am 73: 397–409.
46. Briggs A, Sculpher M, Dawson J, Fitzgerald R, Murray D, et al. (2003)
Modelling the cost-effectiveness of primary hip replacement: how cost-effective is
the Spectron compared to the Charnley prosthesis? York: Centre for Health
Economics, The University of York.
47. Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML (1999) Generic and
condition-specific outcome measures for people with osteoarthritis of the knee.
Rheumatology 38: 870–877.
48. Van Essen GJ, Chipchase LS, O’Connor D, Krishnan J (1998) Primary total
knee replacement: short-term outcomes in an Australian population. J Qual Clin
Pract 18: 135–142.
49. Bennett K, Torrance G, Moran L, Smith F, Goldsmith C (1997) Health state
utilities in knee replacement surgery: the development and evaluation of
McKnee. J Rheumatol 24: 1796–1805.
50. Dawson J, Fitzpatrick R, Murray D, Carr A (1998) Questionnaire on the
perceptions of patients about total knee replacement. J Bone Joint Surg Br 80:
63–69.
51. Heck D, Robinson R, Partridge C, Lubitz R, Freund D (1998) Patient outcomes
after knee replacement. Clin Orthop 356: 93–110.
52. Kiebzak G, Campbell M, Mauerhan D (2002) The SF-36 general health status
survey documents the burden of osteoarthritis and the benefits of total joint
arthroplasty: but why should we use it. Am J Manag Care 8: 463–474.
53. Kiebzak G, Vain P, Gregory A, Mokris J, Mauerhan D (1997) SF-36 general
health status survey to determine patient satisfaction at short-term follow-up
after total hip and knee arthroplasty. J South Orthop Assoc 6: 169–172.
54. Shields R, Enloe L, Leo K (1999) Health related quality of life in patients with
total hip or knee replacement. Arch Phys Med Rehabil 80: 572–579.
55. Jones C, Voaklander D, Johnston D, Suarez-Almazor M (2001) The effect of age
on pain, function, and quality of life after total hip and knee arthroplasty. Arch
Intern Med 161: 454–460.
56. Jones C, Voaklander D, Johnston D, Suarez-Almazor M (2000) Health related
quality of life outcomes after total hip and knee arthroplasties in a community
based population. J Rheumatol 27: 1745–1752.
57. Bachmeier CJ, March LM, Cross MJ, Lapsley HM, Tribe KL, et al. (2001) A
comparison of outcomes in osteoarthritis patients undergoing total hip and knee
replacement surgery. Osteoarthritis Cartilage 9: 137–146.
58. Hozack W, Rothman R, Albert T, Balderston R, Eng K (1997) Relationship of
total hip arthroplasty outcomes to other orthopaedic procedures. Clin Orthop
344: 88–93.
59. Australian Institute of Health and Welfare (2005) Australian hospital statistics
2003-04. Canberra: Australian Institute of Health and Welfare.
60. Australian Government Department of Health and Ageing (2005) National
hospital cost data collection: cost report round 08 (2003-2004) AR-DRGv4.2.
Canberra: Australian Government Department of Health and Ageing.
61. Australian Institute of Health and Welfare (2001) Disease costs and impact study
2000-01. Canberra: Australian Institute of Health and Welfare.
62. March L, Cross M, Tribe K, Lapsley H, Courtenay B, et al. (2002) Cost of joint
replacement surgery for osteoarthritis: the patients’ perspective. J Rheumatol 29:
1006–1014.
63. Australian Bureau of Statistics (2004) Average weekly earnings: November 2003.
Camberra: Australian Bureau of Ststistics.
64. Australian Bureau of Statistics;Persons not in the labour force. Camberra:
Australian Bureau of Ststistics.
65. Australian Institute of Health and Welfare (2005) Health expenditure Australia
2003-04. Canberra: Australian Institute of Health and Welfare.
66. Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PGN, et al.
(1997) Disability weights for diseases in the Netherlands. Rotterdam:
Department of Public Health, Erasmus University.
67. Ware J, Sherbourne C (1992) The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. Med Care 30: 473–483.
68. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient
outcome in arthritis. Arthritis & Rheumatism 23: 137–145.
69. Bellamy N, Buchanan W, Goldsmith C, Campbell J, Stitt L (1988) Validation
study of WOMAC: a health status instrument for measuring clinically important
patient relevant outcomes to antirheumatic drug therapy in patients with
osteoarthritis of the hip or knee. J Rheumatol 15: 1833–1840.
70. EuroQol Group (1990) EuroQol - a new facility for the measurement of health-
related quality of life. Health Policy 16: 199–208.
71. Bayley K, London M, Grunkemeier G, Lansky D (1995) Measuring the success
of treatment in patient terms. Med Care.
72. Mortimer D, Segal L, Sturm J (2009) Can we derive an’exchange rate’between
descriptive and preference-based outcome measures for stroke? Results from the
transfer to utility (TTU) technique. Health and quality of life outcomes 7: 33.
73. Viney R, King M, Savage E, Hall J (2004) Use of the TTU is questionable. The
Medical Journal of Australia 181: 338.
74. The United Nations (2003) Operational Rates of Exchange. New York: United
Nations Treasury.
75. Australian Orthopaedic Association National Joint Replacement Registry (2005)
Annual report supplementary. Adelaide: Australian Orthopaedic Association.
Cost-Effectiveness of Hip and Knee Replacements
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25403